Chronic kidney disease

Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 30, 2025

Language: Английский

---

Cognitive Impairment in Chronic Kidney Disease Across Different Stages: The Role of Structural and Perfusion‐Driven Functional Connectivity Changes

Brain and Behavior, Journal Year: 2025, Volume and Issue: 15(2)

Published: Feb. 1, 2025

ABSTRACT Introduction Chronic kidney disease (CKD) is associated with cognitive impairment (CI), yet the exact pathophysiological mechanisms remain unclear. This study aims to investigate alterations in gray matter volume (GMV) and cerebral blood flow (CBF) across CKD stages, identify co‐changed brain regions, explore abnormal seed‐based functional connectivity (FC) patients CKD, correlation between regions neuropsychological test scores. Methods Two hundred eight participants (66 healthy controls, 70 Stages 1–3a, 72 3b–5) were consecutively recruited underwent high‐resolution T1‐weighted imaging, arterial spin labeling, MR imaging. The imaging parameters compared among three groups, correlations MoCA scores analyzed. Results Compared 1–3a group, bilateral fusiform gyrus (FFG.L FFG.R) exhibited reduced GMV, increased CBF, decreased FFG.L‐FC inferior frontal gyrus, triangular part (IFGtriang.L IFGtriang.R), left middle occipital (MOG.L), hippocampus (HIP.L), as well FFG.R‐FC median cingulate paracingulate gyri (DCG.L DCG.R), superior medial (SFGmed.L), IFGtriang.L, right temporal (MTG.R) 3b–5 group. A negative was observed (MFG.R), IFGtriang.R, HIP.L, putamen 1–3a. Conclusion Brain structural perfusion may underlie FC cognitive‐related providing potential neuroimaging evidence for neuropathological of CI different stages CKD.

Language: Английский

---

Electrochemical platform with Ag/ZnO nanorods for green, blue, and white determination of the newly approved drug roxadustat in pharmaceuticals and plasma: NQS assessment and UN-SDGs alignment

Microchemical Journal, Journal Year: 2025, Volume and Issue: unknown, P. 113326 - 113326

Published: March 1, 2025

Language: Английский

---

CONNECT: what has been done and what needs to be done

Nephrology Dialysis Transplantation, Journal Year: 2025, Volume and Issue: 40(Supplement_2), P. ii1 - ii3

Published: March 1, 2025

Language: Английский

---

Chemotherapy-related cognitive impairment and kidney dysfunction

Nephrology Dialysis Transplantation, Journal Year: 2025, Volume and Issue: 40(Supplement_2), P. ii54 - ii63

Published: March 1, 2025

ABSTRACT Cancer and kidney diseases (KD) intersect in many ways resulting worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated cancer patients by known effects of antineoplastic drugs on cognition, leading to a phenomenon as chemotherapy-related impairment (CRCI). This manifests poor attention span, disturbed short-term memory, general mental sluggishness. literature review explores CRCI investigates the potential impact KD this phenomenon. Additionally, we highlight shared pathogenetic mechanisms (including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, electrolyte, acid-base imbalances), clinical presentation imaging findings between CRCI. The disruption blood–brain barrier might key mechanism for increased brain permeability anticancer nephropathic cancer. Based existing knowledge, found heightened neurotoxicity synergistic potentiation KD. However, further translational research is urgently required validate hypothesis.

Language: Английский

---

Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Cognitive impairment is a prevalent complication in chronic kidney disease (CKD), ranging from mild deficits early stages to more severe conditions, such as cognitive and dementia advanced stages. CKD patients exhibit reduced performance memory, attention, language, visuospatial abilities executive functions. Contributing factors include uraemic toxins, structural brain changes, blood-brain barrier dysfunction, anaemia comorbidities like diabetes mellitus. Malnutrition, affecting nearly half of patients, exacerbates decline through inflammation, oxidative stress protein-energy wasting. Nutritional deficiencies, particularly protein, vitamin D, B vitamins, omega-3 fatty acids antioxidants, are linked impaired cognition. Emerging evidence highlights the role gut-brain axis, with gut-derived toxins microbiome alterations contributing dysfunction. Processed foods microplastics further compound risks by promoting inflammation neurotoxicity. Dialysis transplantation offer opportunities for recovery, though challenges remain, haemodialysis patients. interventions, including tailored protein intake, micronutrient supplementation dietary counselling, critical mitigating decline. Addressing comorbidities, targeted nutritional pharmacological strategies, improves outcomes. Integrating psychological social support enhances quality life, given high prevalence anxiety depression Future research should focus on personalized nutrition, gut microbiota modulation routine assessments optimise care. A holistic approach combining medical, psychosocial strategies essential improving overall health

Language: Английский

---

A novel collaborative signal amplification biosensor based on sandwich-type composite film for ultrasensitive detection of rhEPO

Journal of Applied Electrochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: April 18, 2025

Language: Английский

---

Cognitive impairment in CKD patients: a guidance document by the CONNECT network

Clinical Kidney Journal, Journal Year: 2024, Volume and Issue: 18(2)

Published: Sept. 30, 2024

Cognitive impairment is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). This position paper, developed by the Decline Nephro-Neurology: European Cooperative Target network, provides guidance on epidemiology, risk factors, pathophysiology, diagnosis clinical management of CKD-related cognitive impairment. significantly more common CKD compared general population, particularly those undergoing haemodialysis. The development influenced complex interplay including uraemic neurotoxins, electrolytes acid-base disorders, anaemia, vascular damage, metabolic disturbances comorbidities like diabetes hypertension. Effective screening diagnostic strategies are essential for early identification utilizing assessment tools, neuroimaging circulating biomarkers. impact various drug classes, antiplatelet therapy, oral anticoagulants, lipid-lowering treatments antihypertensive drugs, function evaluated. Management encompass pharmacological non-pharmacological interventions, recommendations optimizing while managing complications. highlights importance addressing through detection, careful medication tailored therapeutic to improve patient outcomes.

Language: Английский

---

Translational research on cognitive impairment in chronic kidney disease

Nephrology Dialysis Transplantation, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 14, 2024

ABSTRACT Cognitive decline is common in patients with acute or chronic kidney disease. Several areas of brain function can be affected, including short- and long-term memory, attention inhibitory control, sleep, mood, eating control motor function. disease shares risk factors cognitive dysfunction people without disease, such as diabetes, high blood pressure, sedentary lifestyle unhealthy diet. However, additional kidney-specific may contribute, uremic toxins, electrolyte imbalances, inflammation, acid–base disorders endocrine dysregulation. Traditional interact to cause damage the blood–brain barrier, induce vascular neurotoxicity neuroinflammation. Here, we discuss recent insights into pathomechanisms from animal models novel avenues for prevention therapy. We focus on a several that influence cognition: barrier disruption, role skeletal muscle, physical activity factor irisin, emerging therapeutic sodium-glucose cotransporter 2 (SGLT2) inhibitors glucagon-like peptide 1 (GLP-1) receptor agonists. Taken together, these studies demonstrate importance providing mechanistic understanding this complex condition their potential explain mechanisms therapies.

Language: Английский

---

Challenges and Recent Advances in Erythropoietin Stability.

Pharmaceutical Development and Technology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 15

Published: Sept. 28, 2024

Erythropoietin (EPO) is a pivotal hormone that regulates red blood cell production, predominantly synthesized by the kidneys and also produced liver. Since introduction of recombinant human EPO (rh-EPO) in 1989 through DNA technology, therapeutic landscape for anemia has been improved. rh-EPO's market expansion substantial, with its application extending across various conditions such as chronic kidney disease, cancer-related anemia, other disorders. Despite success, significant concerns remain regarding stability EPO, which critical preserving biological activity ensuring efficacy under diverse environmental conditions. Instability issues, including degradation loss activity, challenge both drug development treatment outcomes. Factors contributing to instability include temperature fluctuations, light exposure, interactions substances. To overcome these challenges, pharmaceutical research focused on developing innovative strategies stabilizing agents, advanced formulation techniques, optimized storage This review article explores multifaceted aspects stability, examining impact clinical development. It provides comprehensive current stabilization strategies, use excipients, lyophilization, novel delivery systems.

Language: Английский

---